Table 1. Summary of main baseline characteristics and efficacy outcomes.
| Study | Trial phase | Study design | Disease | Line | Intervention | Comparator | Sample size (I/C) |
Median age (I/C) (years) |
Median OS (I/C) (month) |
Median PFS (I/C) (month) |
|---|---|---|---|---|---|---|---|---|---|---|
| McDermott 2018 | II | Multicenter, open-label, randomized | Metastatic renal cell carcinoma | 1L | Atezolizumab + bevacizumab | Sunitinib | 101/101 | 62/61 | NR | 11.7/8.4 |
| Atezolizumab | Sunitinib | 103/101 | 61/61 | NR | 6.1/8.4 | |||||
| Motzer 2019 | III | Multicenter, open-label, randomized, | Advanced renal cell carcinoma | 1L | Avelumab + axitinib | Sunitinib | 442/444 | 62/61 | NR | 13.8/8.4 |
| Rini-1 2019 | III | Multicenter, open-lab, randomly assigned | Advanced renal cell carcinoma | 1L | Pembrolizumab + axitinib | Sunitinib | 432/429 | 62/61 | Not reached | 15.1/11.1 |
| Rini-2 2019 | III | Multicenter, open-label, randomized | Advanced renal cell carcinoma | 1L | Atezolizumab + bevacizumab | Sunitinib | 454/461 | 62/60 | 33.6/34.9 | 11.2/8.4 |
| Socinski 2018 | III | International, open-label, randomly assigned | Metastatic non-squamous NSCLC | 1L | Atezolizumab + bevacizumab + carboplatin + paclitaxel | Bevacizumab + carboplatin + paclitaxel | 400/400 | 63/63 | 19.2/14.7 | 8.3/6.8 |
| Xu 2017 | III | Open-label, active-controlled, randomized | Advanced renal cell carcinoma | 2L | Prior antiangiogenic therapy + nivolumab | Prior anti-angiogenic therapy + everolimus | 410/411 | 62/62 | 25.0/19.6 | 4.6/4.4 |
| Uemura 2019 | III | Multicenter, randomized, open label, | Advanced renal cell carcinoma | 1L | Avelumab + axitinib | Sunitinib | Japanese: 33/34 | 64/65 | Not reached | 16.6/11.2 |
| Reck 2019 | III | International, randomized, open-label | Metastatic non-squamous NSCLC | 1L | Atezolizumab + bevacizumab + carboplatin + paclitaxel | Bevacizumab + carboplatin + paclitaxel | EGFR+: 34/43; liver metastases: 51/56 | 63/63 | EGFR+: not reached /18.7; liver metastasis: 13.3/9.4 | EGFR+: 10.2/6.9; liver metastasis: 8.2/5.4 |
| Atezolizumab + carboplatin + paclitaxel | Bevacizumab + carboplatin + paclitaxel | EGFR+: 45/43; liver metastases: 52/56 | 63/63 | EGFR+: 21.4/18.7; liver metastasis: 8.9/9.4 | EGFR+: 6.9/6.9; liver metastasis: 5.4/5.4 |
C, comparator; EGFR, epidermal growth factor receptor; I, intervention; NR, not reported; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival.